Recombinant 重组人源化OKT3

Cat#: GMP-A018

产品描述:
CytoCares重组人源化OKT3 是在OKT3的基础上,经过人源化改造,并通过基因工程方法生产的 T 细胞激活性抗体。在保持了 OKT3 单抗对T 细胞激活能力的前提下,最大程度上消除了鼠源性抗体的免疫原性,并采用基因工程细胞株生产,真正做到无血清无动物来源,产品的稳定性与安全性得到极大的提高。同时,产品采用药用规格原辅料生产,并严格控制宿主蛋白质残留、核酸残留及常见病原体等,符合 GMP 规范的产品生产与质量管理规程保障生产过程及所有原辅料可追溯。 CytoCares 重组人源化 OKT3 识别人 TCRε链,从而激活 T 细胞活化信号途径,刺激 T 细胞的活化与增值。所有的 T 细胞都有 TCR 表达,因此 CytoCares 人源化 OKT3 还可以用于分离俘获 T 细胞。
特点:
基因工程生产,无血清无动物来源 高度人源化,避免鼠源副作用;药用规格原辅料制备;与 OKT3 相同生物学活性
产品用途:
T 细胞的分离与俘获,T 细胞激活与扩增
使用建议:
在 T 细胞激活与扩增中的应用: 一般应用:推荐浓度为 5-10ug/ml,必要时可针对具体的细胞在5ug/ml-20ug/ml 间选择最佳使用浓度。
保存条件:
-20 ℃保存
制剂(Formulation)
:本品为澄清液体,无白蛋白等动物来源成分。
质量控制:
质量控制:
见瓶身
纯度:>95%
内毒素:<0.1EU/ug
宿主蛋白残留:<1ug /mg
宿主核酸残留:<10pg /mg
常见病原体:阴性

Publication:
Frost Gregory Ian, et al. METHODS OF TRANSDUCING AND EXPANDING IMMUNE CELLS AND USES THEREOF (F1 ONCOLOGY, INC. patent:US20190367876 43804)
The present disclosure provides methods for genetically modifying and expanding immune cells ex vivo, especially for use in cell-based adoptive immunotherapy. As such, method embodiments are provided for transducing immune cells (e.g. T cells and/or NK cells) that include a step of activating the cells and genetically modifying the activated cells, for example by transducing the cells with recombinant retroviral particles, such as lentiviral particles. Genetically modified cells produced by these methods are also provided. Such methods are typically performed within a closed system, and in illustrative embodiments within a single chamber of a closed system. The methods typically include expanding the genetically modified immune cells in cell expansion media within the closed system, in illustrative embodiments within the single chamber of the closed system. As such, provided herein in illustrative embodiments, are fed-batch, single-reactor method systems.
Frost Gregory Ian, et al. CHIMERIC ANTIGEN RECEPTORS AGAINST AXL OR ROR2 AND METHODS OF USE THEREOF (F1 ONCOLOGY, INC. patent:US20190367621 43804)
The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.
Luo Peter Peizhi, et al. ANTI-CD137 MOLECULES AND USE THEREOF (Adagene Inc. patent:US20190055314 2019)
The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
Qian Qijun, et al. EFFICIENT AND SAFE TRANSPOSON INTEGRATION SYSTEM AND USE THEREOF (SHANGHAI CELL THERAPY RESEARCH INSTITUTE patent:US20180265890 2018)
The invention belongs to the field of molecular biology, and relates to an efficient and safe transposon integration system and use thereof. The invention also relates to a nucleic acid construct and use thereof. Preferably, the nucleic acid construct comprises the following elements in order: a 5′-terminal repeat sequence of a transposon, a multiple cloning site, a polyA tailing signal sequence, a 3′-terminal repeat sequence of a transposon, a sequence encoding a transposase and a promoter controlling expression of the transposase; wherein the multiple cloning site is used for operably inserting an exogenous gene and optionally a promoter controlling expression of the exogenous gene; the polyA tailing signal sequence has a polyA tailing signal function in both forward and reverse directions; and the direction of the expression cassette of the transposase is opposite to the direction of the exogenous gene expression cassette. The nucleic acid construct is useful for mediating efficient and safe expression of an exogenous gene in a host cell.
Frost Gregory Ian, et al. METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATED EXPANSION THEREOF (F1 Oncology, SEZC patent:US20170296678 2017)
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.
Frost Gregory Ian, et al. METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF (F1 Oncology, Inc. patent:US20170356010 2017)
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

Please fill in the catno. and batch No., we will contact you asap.